Acute Myocardial Infarction Clinical Trial
Official title:
Early Individualized-exercise Based Cardiac Rehabilitation Program in Patients With a Recent Acute Myocardial Infarction (EARLYmyo-CRPⅡ): Study Protocol for a Randomised Controlled Trial
Acute myocardial infarction (AMI) is a life-threatening condition and a cause of functional disability. After reperfusion therapies and pharmacological strategies, patients suffered great pain physically and mentally. How to improve the quality of life and the prognosis in patients with AMI is a hot topic in the field of cardiac rehabilitation now. In this study, a randomized, controlled and prospective clinical trial is designed for patients with AMI to improve exercise capacity, cardiometabolic parameters, as well as quality of life by an individualized, low-cost exercise intervention we developed after evaluation by Cardiopulmonary Exercise Tests (CPET). Serial CPET are performed to prospectively measure changes in aerobic exercise capacity, and the MOS item short form health survey(SF-36)are constructed to survey life quality. What's more, echocardiography and NT-proBNP are also assessed.
Status | Not yet recruiting |
Enrollment | 160 |
Est. completion date | February 1, 2023 |
Est. primary completion date | August 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion criteria 1. Acute myocardial infarction (AMI) within 1 months prior to recruitment. 2. Complete revascularization. 3. Man or non- pregnant women aged from 18 to 80 years. Exclusion criteria 1. Uncontrolled hypertension (systolic blood pressure/diastolic blood pressure >160/100 mmHg),or symptomatic hypotension. 2. Significant resting electrocardiogram abnormalities (left bundle branch block, non-specific intraventricular conduction delay, left ventricular hypertrophy, resting ST-segment depression), life-threatening cardiac arrhythmias. 3. Acute myocarditis, pericarditis or acute systemic illness. 4. Those who are assessed by the doctor as high-risk [12]. 5. Pacemaker or implantable cardioverter defibrillator. 6. Any contraindication to exercise testing or exercise training or inability to complete a CPET. 7. Life-threatening diseases with limited life expectancy <3 year. 8. Uncontrolled unstable angina pectoris. 9. Significant valvular disease (mitral stenosis, moderate to severe mitral insufficiency, aortic stenosis, or aortic insufficiency, severe mitral / aortic regurgitation). 10. Severe mental or cognitive impairment. 11. Inability to follow the procedures of the study. |
Country | Name | City | State |
---|---|---|---|
China | RenJi Hospital, Shanghai JiaoTong University, School of Medicine | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
RenJi Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Peak oxygen consumption (VO2)change | Difference in the interval changes from baseline to 3 months and 6 months in peak VO2 comparing Experimental group with control. | Baseline, 3, 6 months | |
Secondary | Ventilatory efficiency (VE/VCO2 slope) change | Difference in the interval changes from baseline to 3 months and 6 months in Ventilatory efficiency (VE/VCO2 slope) comparing experimental group with control. | Baseline, 3, 6 months | |
Secondary | oxygen consumption (VO2) at anaerobic threshold | Difference in the interval changes from baseline to 3 months and 6 months in VO2 at anaerobic threshold comparing Experimental group with control. | Baseline, 3, 6 months | |
Secondary | Oxygen uptake related to work rate(?VO2/?WR)change | Difference in the interval changes from baseline to 3 months and 6 months in Oeygen uptake related to work rate(?VO2/?WR)comparing experimental group with control. | Baseline, 3, 6 months | |
Secondary | Peak /AT Oxygen Pulse (O2-Pulse)change | Difference in the interval changes from baseline to 3 months and 6 months in Peak /AT Oxygen Pulse (O2-Pulse) comparing experimental group with control. | Baseline, 3, 6 months | |
Secondary | Peak metabolic equivalent (MET) change | Difference in the interval changes from baseline to 3 months and 6 months in peak metabolic equivalent (MET) change comparing experimental group with control. | Baseline, 3, 6 months | |
Secondary | Heart rate variability | Difference in the interval changes from baseline to 3 months and 6 months in Heart rate variability comparing experimental group with control. | Baseline, 3, 6 months | |
Secondary | Body mass index(BMI)change | Difference in the interval changes from baseline to 3 months and 6 months in Body mass index(BMI)comparing experimental group with control. BMI is the value obtained by dividing body weight by height square (weight in kilograms, height in meters). BMI is a standard commonly used in the world to measure the degree of obesity and health of the human body. | Baseline, 3, 6 months | |
Secondary | LVEF change | Difference in the interval changes from baseline to 3 months and 6 months in LVEF comparing experimental group with control. | Baseline, 3, 6 months | |
Secondary | NT-proBNP(pg/ml) | Difference in the interval changes from baseline to 3 months and 6 months in NT-proBNP comparing Experimental group with control. | Baseline, 3, 6 months | |
Secondary | The MOS item short form health survey(SF-36) | Difference in the interval changes from baseline to 3 months and 6 months in The MOS item short form health survey(SF-36) comparing experimental group with control. | Baseline, 3, 6 months | |
Secondary | The occurrence and composite of major adverse cardiac events (MACE) | Major adverse cardiac events (MACE) included all-cause mortality, non-fatal myocardial infarction and coronary revascularisation. we check the outcome in 3 months and 6 months. | 3, 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04451967 -
Acute Myocardial Infarction Study in Northeastern China
|
||
Completed |
NCT05974397 -
Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan
|
||
Not yet recruiting |
NCT04072081 -
Drug-coated Balloon Versus Drug-eluting Stent in the Treatment of Coronary Artery Lesions in STEMI Patients in De Novo Coronary Lesions
|
N/A | |
Recruiting |
NCT03940443 -
Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
|
||
Recruiting |
NCT03707626 -
Collateral Circulation to LAD and Wellens Sign
|
||
Completed |
NCT02669810 -
EXCELLENT (EXpanded CELL ENdocardiac Transplantation)
|
Phase 2 | |
Not yet recruiting |
NCT04104048 -
Short Term Outcome of Primary Precutaneous Coronary Intervention in Ostial Versus Non Ostial Culprit Proximal Left Anterior Descending Artery Acute Myocardial Infraction
|
||
Active, not recruiting |
NCT02915107 -
The SORT OUT IX STEMI OCT Trial
|
N/A | |
Completed |
NCT02896543 -
The Relationship of Change of Dendritic Cells Fractalkine and P-selectin Patients With Acute Myocardial Infarction
|
N/A | |
Completed |
NCT02531165 -
Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
|
N/A | |
Completed |
NCT02490969 -
Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19
|
N/A | |
Withdrawn |
NCT01901471 -
Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock
|
Phase 2 | |
Completed |
NCT02312336 -
A Pilot Study of Transcoronary Myocardial Cooling
|
N/A | |
Recruiting |
NCT02071342 -
Study of ABSORB Stent in Acute Myocardial Infarction
|
N/A | |
Completed |
NCT02070913 -
COOL-AMI EU Case Series Clinical Study
|
||
Terminated |
NCT01972126 -
MAGNetic QRS-Fragmentation in Patients With Myocardial InfarcTion and Moderately RedUceD Ejection Fraction
|
N/A | |
Withdrawn |
NCT01678339 -
Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients
|
N/A | |
Completed |
NCT01887080 -
Effects of Microcurrent in a Cardiovascular Rehabilitation Home-based Program
|
N/A | |
Completed |
NCT01216995 -
Safety and Efficacy of Adipose Derived Regenerative Cells (ADRCs) Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction (AMI)
|
Phase 2 | |
Completed |
NCT01673893 -
ClearWay Rx Readmission Registry
|